Physician profile
David E Greenberg
NPI 1477871184
$18,121.94
in general payments reported to CMS, 2019-2025
10 companies · $5,818 in 2025
The $5,818 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $2,361 · 2021: $2,081 · 2022: $1,941 · 2023: $5,506 · 2024: $37.66 · 2025: $5,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,287 · Consulting Fee: $3,880 · Food and Beverage: $1,977 · Travel and Lodging: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,286.78 |
| Consulting Fee | $3,880.00 |
| Food and Beverage | $1,976.93 |
| Travel and Lodging | $217.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $11,456.61 | 2019-2025 | Fetroja |
| Sarepta Therapeutics, INC. | $3,550.00 | 2020-2022 | |
| Janssen Research & Development, LLC | $2,650.00 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $113.56 | 2021-2023 | Nuzyra |
| Biomerieux INC | $100.00 | 2025 | |
| Merck Sharp & Dohme LLC | $90.54 | 2019 | |
| Nabriva Therapeutics, Plc | $70.40 | 2020 | |
| Melinta Therapeutics, LLC | $47.04 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $43.79 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.